14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRSP vs ACLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Arcellx, Inc. (ACLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACLX carries 61.7/100 (BUY) at $115.07 (61.7x Forward P/E, -3850.2% operating margin).
Composite vs. Pillar Nuance: While ACLX currently prints a higher short-term Unified Composite Score (61.7/100 BUY vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -3850.2% operating margin) and revenue trajectory (+1325.1% vs. -89.2% YoY).
Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ACLX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRSP vs ACLX. Trailing 12-month operating profitability (CRSP -2058.6% vs ACLX -3850.2%) and valuation multiples (CRSP 23.4x vs ACLX 61.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $6.7B market capitalization and -3850.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRSP vs ACLX Key Questions & Quantitative Answers
As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Arcellx, Inc. (ACLX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACLX carries 61.7/100 (BUY) at $115.07 (61.7x Forward P/E, -3850.2% operating margin). Composite vs. Pillar Nuance: While ACLX currently prints a higher short-term Unified Composite Score (61.7/100 BUY vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -3850.2% operating margin) and revenue trajectory (+1325.1% vs. -89.2% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ACLX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with ACLX at -89.2% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (N/A gross margin, -3850.2% operating margin). On trailing 12-month operating scale, CRSP generates $25M in USD-normalized revenue versus $22M for ACLX. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACLX.
CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ACLX trades at 61.7x Forward P/E, 61.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus ACLX (-53.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, ACLX carries 1.5% implied volatility (1st %ile, Compressed (<25th %ile)), a 9.73x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.83β · 1% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.